A Randomised, Double-Blind, Placebo-Controlled, 3-Period Crossover Study to Assess the Efficacy and Safety of Single Dose Intranasal GSK1004723 Compared With Placebo in an Allergen Challenge Chamber in Male Subjects With Seasonal Allergic Rhinitis.
Phase of Trial: Phase II
Latest Information Update: 26 May 2012
At a glance
- Drugs GSK 1004723 (Primary)
- Indications Seasonal allergic rhinitis
- Focus Therapeutic Use
- 26 May 2012 Planned number of patients is 54 as reported by European Clinical Trials Database.
- 26 May 2012 New source identified and integrated (EudraCT2008-001567-10 European Clinical Trials Database).
- 22 Jan 2009 New trial record.